The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

Shares of Moderna (NASDAQ:MRNA) jumped 5% following reports that it had been awarded $590 million for the development of a ...

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...